Salzman & Colburn () evidenciaram que Slotman, K. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN B, SENAN S. Kumar,. Radiobiological. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. . Slotman BJ, van Tinteren H, Praag JO, et al. Stereotactic Slotman B, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. (). Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. , & Reijneveld, S. Experiences of case managers in providing. Planning of radiotherapy capacity and productivity. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Quality of life. J Thorac Oncol. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN BJ, VOS PH. Kim, & Blakeney, ). Radiother. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Treatment of stage I NSCLC in elderly patients: a. Oncol. ; (2), KIM MS et al. Slotman BJ, Senan S.